Pharma
Architectural Constraints and Failure Modes in AI-Driven Drug Discovery Programs
AI programs in pharmaceutical R&D fail for specific, architectural reasons. Understanding these failure modes before building is not theoretical caution — it is the difference between programs that produce actionable outputs and programs that consume budget without advancing drug development. This article documents the most common architectural constraints encountered in AI-driven discovery programs and maps […]
AI-Assisted Drug Discovery: Why Governed Data Is the Rate Limiter, Not Model Capability
The pharmaceutical industry has invested heavily in artificial intelligence over the past decade. The results have been uneven — not because the models are inadequate, but because the data feeding those models is. In project after project, the root cause of AI failure in drug discovery is not model architecture. It is the quality, consistency, […]
The $2.6 Billion Lesson: What Pharma’s Failed Drug Programs Reveal About Data Governance
Developing a single approved drug costs an average of $2.6 billion when the full portfolio of failures is factored in. That figure, widely cited from research in the Journal of Health Economics, is not primarily a chemistry problem or a clinical science problem. It is, in large part, a data governance problem—and the pharmaceutical industry […]